Article: Afinitor(R) (everolimus) Now Licensed in UK for Advanced Kidney Cancer Patients After Failure of First Line Vascular Targeted Therapy (1,2).

FRIMLEY, England, September 24 /PRNewswire/ --

- This Press Release is Intended for Consumer Media Only

- Afinitor More Than Doubles the Median Time Without Tumour Growth and Reduces the Risk of Disease Worsening or Death by 67% Compared With Placebo (2)

- Patients With Advanced Kidney Cancer Have Limited Options Once Tumours Progress After First Line Standard Therapy(3)

- Recently Published UK Expert Clinical Consensus Recommend Afinitor as Second-Line Therapy for Advanced Kidney Cancer Based on Class I Evidence(4)

Afinitor(R) (everolimus) has recently been licensed for the treatment of advanced kidney cancer after failure ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!